CPRX Long Call Strategy

CPRX (Catalyst Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX (Catalyst Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.81B, a trailing P/E of 17.21, a beta of 0.72 versus the broader market, a 52-week range of 19.05-32.56, average daily share volume of 1.8M, a public-listing history dating back to 2006, approximately 181 full-time employees. These structural characteristics shape how CPRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.72 places CPRX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long call on CPRX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current CPRX snapshot

As of May 15, 2026, spot at $31.16, ATM IV 5.20%, IV rank 0.92%, expected move 1.49%. The long call on CPRX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on CPRX specifically: CPRX IV at 5.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a CPRX long call, with a market-implied 1-standard-deviation move of approximately 1.49% (roughly $0.46 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CPRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on CPRX should anchor to the underlying notional of $31.16 per share and to the trader's directional view on CPRX stock.

CPRX long call setup

The CPRX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CPRX near $31.16, the first option leg uses a $31.16 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CPRX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CPRX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$31.16N/A

CPRX long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

CPRX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on CPRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on CPRX

Long calls on CPRX express a bullish thesis with defined risk; traders use them ahead of CPRX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

CPRX thesis for this long call

The market-implied 1-standard-deviation range for CPRX extends from approximately $30.70 on the downside to $31.62 on the upside. A CPRX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CPRX IV rank near 0.92% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CPRX at 5.20%. As a Healthcare name, CPRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CPRX-specific events.

CPRX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CPRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CPRX alongside the broader basket even when CPRX-specific fundamentals are unchanged. Long-premium structures like a long call on CPRX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CPRX chain quotes before placing a trade.

Frequently asked questions

What is a long call on CPRX?
A long call on CPRX is the long call strategy applied to CPRX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CPRX stock trading near $31.16, the strikes shown on this page are snapped to the nearest listed CPRX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are CPRX long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CPRX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 5.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CPRX long call?
The breakeven for the CPRX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CPRX market-implied 1-standard-deviation expected move is approximately 1.49%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on CPRX?
Long calls on CPRX express a bullish thesis with defined risk; traders use them ahead of CPRX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current CPRX implied volatility affect this long call?
CPRX ATM IV is at 5.20% with IV rank near 0.92%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related CPRX analysis